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Currently most genetic association studies are undertaken using 
common variants which tend to have small relative risks for 
common diseases. This prompts an approach to characterising 
the genetic contribution to disease through use of aggregate 
scores of risk alleles which can explain non-trivial propor-
tions of variance in disease risk. Indeed the majority of common 
complex diseases and phenotypes are likely to be influenced by 
hundreds, if not thousands of common variants of small effect 
scattered across the genome1. This means that there is information 
in the mass of common variants that individually are not 
considered to be statistically significant in a genome-wide asso-
ciation study. Allelic scores constructed from thousands of 
common variants (usually single-nucleotide polymorphisms, 
SNPs) across the genome can be used even without explicit 
knowledge of the mode of contribution of each variant, as the 
aggregate score uses all common genotypic contributions to 
explain the variance in the trait concerned2–4. Taken together, 
aggregate genetic risk can be one of the strongest single risk 
factors for a common disease, given the substantial heritability 
of most traits5.
We should also bear in mind that most genetic association stud-
ies for complex traits are underperforming. Nearly all genetic 
associations are discovered through the analysis of data 
collected in cross-section. In most instances, prevalent cases or 
spot measurements are used in studies systematically hunting for 
correlations between phenotypes and SNPs. However, whilst it is 
known that genetic data is temporally stable (for the most part), 
the same cannot be said for phenotypic assessment. Consequently, 
the failure to measure outcomes adequately (i.e. in true longi-
tudinal, or incident fashion) will at the very least compromise 
analytical power and cloud the inference from genetic association. 
Furthermore, it is increasingly clear that when longitudinal data 
are assessed, quite different patterns of association and variance 
explained can be revealed6,7. At certain points in the life course, 
then, the genetic risk of an individual may well be much more 
predictive than initially suggested by available association studies.
So if we are racing towards a world of improved genotyp-
ing scale and better studies of phenotypic association, what 
should we do with this information? The direct use of human 
genetic data in directing pharmaceutical development8 and in 
causal inference analyses9 has had a marked impact. However, 
if we regard genetic data as another tool of measurement in the 
hands of clinicians attempting to describe or predict the biologi-
cal condition of an individual – the “genetic sphygmomanom-
eter” – a natural question is: what is there to be gained from 
adding this particular information to the history taking 
process? It is well known that predicting the health trajec-
tory of an individual is made enormously complicated by the 
idiosyncrasies of patients and the events of chance10; so can 
genetic data be of any use? The answer must ultimately be yes as 
a more precise measurement of family history, but this does not 
have to be considered wholly via conventionally defined causal 
pathways – the detection of which suffers a natural, genetic 
architecture versus analytical power limited, aggregate predictive 
ability.
Taking the example of cancer, it is possible to generate a genome-
wide aggregate score, from birth, which explains some of the 
risk of presenting with a malignant neoplasm later in life11–13. 
This is, of course, a combination of both direct pathway effects, 
but also relationships derived from the heritable contributions to 
any predicting factor – causal or otherwise. Done for each indi-
vidual in a population of common ancestry to discovery studies 
educating the location of genetic risk, this would allow any one 
person to be located in a distribution of scores summarising the 
common genetic contribution to cancer risk. Position in this 
distribution is of course not a reason for immediate intervention 
with, say, a regime of growth factor inhibitors from the moment 
of full maturity, but it may offer information that could warrant 
something as simple as a more regular check-up regime through 
life. Such a non-invasive subject specific augmentation of basic 
clinical consultation could be the only intervention, but one 
which over thousands of individuals would yield life extend-
ing marginal returns at a rate greater than chance. The pro-
posal here is that the routine incorporation of genetic data into 
clinicians’ hands will provide an informative addition to the 
standard tool kit.
Such a mechanism would be possible given two core compo-
nents. The first is a centralised repository of the results of the 
largest, most well conducted genome-wide association studies. 
This would include as many disease outcomes as possible, though 
would only include studies of suitable rigor and with contribu-
tory information. Early versions of such repositories have already 
been published9,14–16. Genetic epidemiologists have a growing 
collection of formidable meta-analyses that summarise effects 
by variant across the genome for hundreds of thousands of indi-
viduals. Made central, they could be easily accessed to provide 
disease specific genetic scores for any individual, which could 
then be used to assign that person to an augmented regime of 
non-invasive, lifecourse, follow-up.
Secondly, to achieve population scale benefits this approach 
requires all members of the population to have a comprehen-
sive screen of common genetic variants which could be matched 
to the reference panel “du jour” in order to provide the material 
for generating individual aggregate risk scores. The actual use of 
these, from a consent point of view, would be the sole decision 
of the genotyped party (or executive) and these data could be 
linked to electronic health records for further clinical investiga-
tion if so required later in life or as the value of these data changes 
with technological advance.
A key element of this use of genetic data at population scale is 
the likely cost implication of personalised courses of check-ups 
(clinical assessment) versus the usual lifecourse clinical experi-
ence. This is a calculation which must involve a consideration 
of the effectiveness of altering the frequency of assessments 
for a person in the tails of a disease risk profile versus the cost 
of regular service. Factors that affect these calculations include 
not only the cost of assessment but also that of implementing 
more personalised programmes and of the resultant rates of over- 
and under-diagnosis of multiple conditions17. However the cost 
of the genome-wide screening itself can be regarded as negligible 
once it is conducted routinely, given that the benefit is distributed 
across a spectrum of health outcomes, in contrast to measurement 
of risk markers such as lipoproteins that are specific to certain 
classes of disease and must be repeatedly measured over time. 
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Furthermore, there is the societal or ethical cost to those located 
in the lower part of the risk profile. This may generate knee-
jerk feelings of discrimination or injustice, however in light 
of our knowledge of common genetic effects of this nature 
(especially their interplay with the true non-genetic environment) 
is only as threatening as conventional diagnoses which themselves 
sit on a continuum of determinism. Indeed, as patients, we seem 
relaxed with the idea of having our own unique balance of phe-
notypic abnormality measured by a combination of crude instru-
ments and clinician eye, but we remain strangely disturbed by 
the notion of having an additional source of information (which 
may at least be measured more precisely) used in the same 
examination.
Similarly, concerns that individuals may prefer not to know 
of their increased genetic risk seem to overlook how most of 
us live more or less easily with the knowledge of genuinely 
non-modifiable risk factors, age and sex. These concerns may 
originate from perceptions of genetic determinism occurring in 
rare genetic diseases, and the burden may be on genetic epidemi-
ologists to effectively convey the probabilistic nature of genetic 
risk in complex disease. That said, few parents would endorse 
the removal of any part of a physician’s toolkit when having a 
child assessed or diagnosed. We should therefore in principle 
not feel any different about genetics when delivered appropri-
ately. Even if it is perceived as undesirable or unethical to know 
genetic risk in advance of disease, once disease is established 
we may wish to rationalise the hand of fate by asking whether 
there was a genetic origin.
Can we test this approach? What guarantee is there that the for-
mulation of differing check-up regimes will, in time, yield favour-
able outcomes for those subjected to them versus normal access to 
clinical services? The obvious step is to undertake a randomized 
controlled trial in a design comparable to some already 
ongoing in the UK and elsewhere, for example the ProtecT trial18 
concerning prostate cancer outcomes following randomly allocated 
screening. Under these conditions it would be practical to exam-
ine the impact of differential rates of clinical assessment through 
the lifecourse in strata assigned by aggregate genotypic scores 
for disease outcomes of choice. A study of this nature would not 
only give evidence of the value of this type of approach to real-
ise, at population scale, the utility of the small effects of common 
genetic variants when combined en masse. It would also allow 
for health economic, ethical and participant experience analy-
ses to be undertaken and further studies to be designed to bring 
forward genetic data as yet another part of the clinical tool kit.
This comment was first drafted in 2012 and whilst no longer 
potentially novel19,20, is worth blowing the dust off. In the last 
five years there has been an explosive development of genetic 
association studies, and increasing emphasis on paradigms of 
precision medicine. Indeed most recent initiatives in the world 
of genome-wide association studies have shown potential 
utility in prediction which may be the opening confirmation of 
this thesis21–23. Coupled with this is the observation that with the 
human genetics community continuing to pursue studies of ever 
increasing magnitude and power, then the ability to detect the 
heritable contribution to the most distal and complex of human 
phenotypes (including behaviour which in itself opens the door 
for altered environmental exposure) is increasing. Consequently 
the capacity for genetic studies to predict complex outcomes 
increases (de facto) and we are left in a position where (i) genetic 
prediction may not only be a flag of rare syndromes, but a 
reasonable guide by which one might tailor lifecourse clinical 
interaction, a form of “precision” medicine, (ii) we seek to iden-
tify the truly environmental factors contributing to disease as unlike 
measuring genetic variation, this does not have an informa-
tion threshold beyond which further measurement is redundant 
(i.e. the challenge of tracking true non-shared environment at 
the individual level) and (iii) we need to challenge the infer-
ence from genetic association studies perceived to add clarity 
through biological/molecular insight - sampling frame, power, 
genetic architecture and the type of genetic study all contribute to 
complexities in inference24. For common genetic variation and 
complex traits, the future should not only be causation and 
dissection of the wealth of new signals, but also the acceptance 
of complexity and the prediction of low-cost, lifecourse shifts 
in the way we interact with clinical service providers.
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